Results 261 to 270 of about 11,453 (281)
Some of the next articles are maybe not open access.
Pharmacological Properties of Antifungal Drugs with a Focus on Anidulafungin
Drugs, 2009Drug classes for the treatment of invasive fungal infections include the polyenes, the triazoles and the echinocandins. Older agents such as the commonly used amphotericin B have a number of limitations, including toxicity and requirements for monitoring during treatment.
MAZZEI, TERESITA, NOVELLI, ANDREA
openaire +4 more sources
Tissue Distribution of Anidulafungin in Neonatal Rats
Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2012Anidulafungin, an echinocandin, is currently approved for treatment of fungal infections in adults. There is a high unmet medical need for treatment of fungal infections in neonatal patients, who may be at higher risk of infections involving bone, brain, and heart tissues. This in vivo preclinical study investigated anidulafungin distribution in plasma,
Jian Lin +10 more
openaire +3 more sources
Anidulafungin: A new echinocandin with a novel profile
Clinical Therapeutics, 2005Until recently, available treatment for serious fungal infections comprised amphotericin B and azoles, which have limitations. Renal toxicity is a major concern with amphotericin B, while drug-drug interactions, hepatotoxicity, and skin rashes are the primary concerns with the azole medications.
openaire +3 more sources
Anidulafungin, a new antifungal drug
Antibiotiques, 2007Resume Objectifs L’essor de nouvelles molecules d’antifongiques est lie au developpement des candidoses invasives ainsi qu’a l’apparition de resistances aux molecules plus anciennes. Methodes La recherche au sein de l’Industrie Pharmaceutique et au moyen de la consultation des donnees publiees nous a permis de reconnaitre une nouvelle classe d ...
openaire +2 more sources
Anidulafungin: a new echinocandin for candidal infections
Expert Review of Anti-infective Therapy, 2007Anidulafungin, a new echinocandin, has recently been approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritonitis and intra-abdominal abscesses in non-neutropenic patients. It is fungicidal against Candida spp.
Annette C. Reboli, Pola de la Torre
openaire +3 more sources
Anidulafungin was noninferior to fluconazole for invasive candidiasis
ACP Journal Club, 2008Source Citation Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med.
openaire +3 more sources
Anidulafungin in the treatment of patients with invasive candidiasis
International Journal of Antimicrobial Agents, 2008Echinocandins have emerged as important agents for the treatment of invasive candidiasis. Forthcoming guidelines are expected to recommend an echinocandin agent as initial primary therapy in patients who are severely ill and/or have risk factors for azole resistance.
Daniel H. Kett, G Fernando Cubillos
openaire +3 more sources
Anidulafungine : perspectives cliniques en 2007
Réanimation, 2007Resume Les candidoses invasives representent une complication nosocomiale grave et redoutee, tout particulierement dans les services de reanimation. La mise a disposition recente de nouveaux antifongiques pour les cliniciens est un des reflets du poids croissant des pathologies invasives liees a des micro-organismes fongiques a l’hopital au cours de ...
Olivier Lortholary, Olivier Lortholary
openaire +2 more sources
Anidulafungin: A Novel Echinocandin for Candida Infections
Future Microbiology, 2008A third echinocandin, anidulafungin, has recently been approved for Candida infections in the non-neutropenic patient. In the EU it is indicated for invasive candidiasis; in 2006 it was approved in the USA for candida esophagitis, candidemia, and two types of invasive infections, peritonitis and intra-abdominal abscesses.
Annette C. Reboli +2 more
openaire +3 more sources